Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/32441
Type
ArticleCopyright
Restricted access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record
INCIDENCE RATES OF NEUROTROPIC-LIKE AND VISCEROTROPIC-LIKE DISEASE IN THREE DENGUE-ENDEMIC COUNTRIES: MEXICO, BRAZIL, AND MALAYSIA
Viscerotrópica
Neurotrópico
Dengue-endêmico
Author
Affilliation
Sanofi Pasteur. Lyon, France.
Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
University Hospital Dr. José E. González. Faculty of Medicine Universidad Autonoma de Nuevo León. Monterrey N.L., Mexico.
Hospital Raja Permaisuri Bainun. Ipoh, Perak, Malaysia.
Clinical Research Centre. Malaysia.
Sanofi Pasteur. Lyon, France.
Sanofi Pasteur. Asia & JPAC Region, Singapore.
Sanofi Pasteur LATAM. Coyoacán, CDMX, Mexico.
Sanofi Pasteur LATAM. Coyoacán, CDMX, Mexico.
Sanofi Pasteur. Clinical Development. Marcy l’Etoile, Lyon, France.
Sanofi Pasteur. Toronto, Canada.
Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
University Hospital Dr. José E. González. Faculty of Medicine Universidad Autonoma de Nuevo León. Monterrey N.L., Mexico.
Hospital Raja Permaisuri Bainun. Ipoh, Perak, Malaysia.
Clinical Research Centre. Malaysia.
Sanofi Pasteur. Lyon, France.
Sanofi Pasteur. Asia & JPAC Region, Singapore.
Sanofi Pasteur LATAM. Coyoacán, CDMX, Mexico.
Sanofi Pasteur LATAM. Coyoacán, CDMX, Mexico.
Sanofi Pasteur. Clinical Development. Marcy l’Etoile, Lyon, France.
Sanofi Pasteur. Toronto, Canada.
Abstract
The background incidence of viscerotropic- (VLD) and neurotropic-like disease (NLD) unrelated to immunization in dengue-endemic countries is currently unknown. Methods: This retrospective population-based analysis estimated crude and standardized incidences of
VLD and NLD in twelve hospitals in Brazil (n = 3), Mexico (n = 3), and Malaysia (n = 6) over a 1-year period
before the introduction of the tetravalent dengue vaccine. Catchment areas were estimated using publicly
available population census information and administrative data. The denominator population for incidence
rates was calculated, and sensitivity analyses assessed the impact of important assumptions.
Results: Total cases adjudicated as definite VLD were 5, 57, and 56 in Brazil, Mexico, and Malaysia, respectively.
Total cases adjudicated as definite NLD were 103, 29, and 26 in Brazil, Mexico, and Malaysia,
respectively. Crude incidence rates of cases adjudicated as definite VLD in Brazil, Mexico, and Malaysia
were 1.17, 2.60, and 1.48 per 100,000 person-years, respectively. Crude incidence rates of cases adjudicated
as definite NLD in Brazil, Mexico, and Malaysia were 4.45, 1.32, and 0.69 per 100,000 person-years,
respectively.
Conclusions: Background incidence estimates of VLD and NLD obtained in Mexico, Brazil, and Malaysia
could provide context for cases occurring after the introduction of the tetravalent dengue vaccine.
Keywords in Portuguese
Vacina tetravalente contra dengueViscerotrópica
Neurotrópico
Dengue-endêmico
Share